1) Validates use of Human-on-a-Chip system to mimic disease mechanisms of rare autoimmune neuropathies that cannot be replicated in animal models.
2) Efficacy data from microphysiological system supported the authorization of a clinical study (NCT04658472) in 2021 through collaboration with Sanofi.